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ABSTRACT
While increasing numbers of cytomegalovirus (CMV)-associated diseases are occurring in patients
undergoing conventional chemotherapy, information regarding CMV reactivation is limited. This
pilot study was conducted to investigate CMV reactivation induced by chemotherapy. Seven blood
samples were collected from each of 15 patients with newly diagnosed malignant disease, at baseline
before chemotherapy, and once every month after chemotherapy was commenced. CMV viral loads
in leukocytes were determined by real-time PCR. Host responses to changes in viral loads were
assessed by assaying CMV-speciﬁc IgG titres and tumour necrosis factor (TNF)-a and interferon
(IFN)-c levels in each of the blood samples, and by scoring the number of CMV-associated clinical
symptoms that developed. All except one patient experienced CMV reactivation during the course of
chemotherapy, with the average viral load peaking after the third course of treatment. Titres of
CMV-speciﬁc IgG increased in line with the increase in viral load. Plasma levels of TNF-a and IFN-c
initially decreased from baseline, and then rose to peak levels at the same time as, or shortly after,
the highest viral loads were recorded. Clinical symptoms potentially attributable to CMV infection
appeared as the viral load increased. It was concluded that the incidence of CMV reactivation in
patients receiving conventional chemotherapy is high. Reactivation is not asymptomatic, but was
self-limiting in most of these cases. Increases in plasma TNF-a and IFN-c occur after reactivation, but
not before.
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INTRODUCTION
Cytomegalovirus (CMV) establishes a life-long
relationship with its host via a latent infection.
Patients with compromised immunity, including
those with human immunodeﬁciency virus infec-
tion, malignancies and organ transplants, or indi-
viduals receiving immunosuppressive therapy,
are at high risk for reactivation of latent CMV. At
present, most knowledge regarding CMV reacti-
vation has come from studies of transplant
recipients and AIDS patients [1–3]. However,
increasing numbers of patients receiving
chemotherapy who experience symptomatic
CMV reactivation have been observed, although
there are few published data concerning this
phenomenon [4].
CMV reactivation is usually deﬁned on the
basis of direct or indirect evidence of virus
activity (e.g., seroconversion, isolation of the virus
from any body site, or direct detection of CMV
antigen). Individuals experiencing CMV reactiva-
tion may develop generalised signs and symp-
toms (e.g., fever, malaise, leukopenia), various
site-speciﬁc CMV-associated syndromes (e.g.,
interstitial pneumonitis, hepatitis, gastroenteritis,
or retinitis) [5], or a potentially fatal dissemi-
nated infection, particularly if the patient is
immunosuppressed [6]. Real-time quantitative
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PCR provides some advantages for measuring
CMV DNA as compared to traditional methods,
e.g., pp65-antigenaemia [7], viral culture and
mRNA sequence-based ampliﬁcation [8]. In the
present study, patients with newly diagnosed
cancer were monitored to determine whether the
CMV viral load increased when they received
chemotherapy and to evaluate host responses to
changes in viral load.
MATERIALS AND METHODS
Patients
The study was approved by the Mackay Memorial Hospital
Institutional Review Board (Taipei, Taiwan), and informed
consent was obtained from all participants (Clinical Trial
Registration: NCT00366717; http://www.clinicaltrials.gov).
Patients with newly diagnosed malignant disease who were
expected to receive chemotherapy for ‡6 months were eligible
for inclusion in the study. Between May 2005 and January
2006, 20 patients with various malignancies were recruited, of
whom 15 completed the study. All patients received chemo-
therapy approximately once a month. Blood (c. 10 mL) was
collected from each participant before the initiation of chemo-
therapy, and once-monthly after each course of chemotherapy.
In total, seven blood samples were collected from each of the
participants. Patients 1, 2, 3, 5, 7, 9, 10, 13, 14 and 15 received
cisplatin 100 mg ⁄m2 on day 1, and 5-ﬂuorouracil
1000 mg ⁄m2 ⁄day on days 1–4. Patients 4 and 6 received
5-ﬂuorouracil 400 mg ⁄m2 ⁄day on days 1–5, and leukovorin
200 mg ⁄m2 ⁄day on days 1–5. Patient 8 received epirubicin
50 mg ⁄m2 on day 1, and vincristine 1.4 mg ⁄m2 on days 1 and
8. Patient 11 received cisplatin 120 mg ⁄m2 on day 1, and
etoposide 100 mg ⁄m2 ⁄day on days 1–3. Patient 12 received
geﬁtinib 500 mg ⁄day for 14 days, followed by 14 days of no
treatment.
Quantitative PCR
Total genomic DNA was extracted from buffy coat samples
using a QIAamp DNA Blood Mini Kit (Qiagen, Valencia,
CA, USA) according to the manufacturer’s instructions, and
was stored at )40C. In brief, buffy coat samples were
prepared by low-speed centrifugation of whole blood for
10 min at room temperature, followed by lysis of red blood
cells with lysis buffer (0.16 M ammonium chloride, 0.01 M
sodium bicarbonate, 0.1 mM EDTA) following removal of
plasma. The cells were washed twice with phosphate-
buffered saline. Total cells were counted and resuspended
in phosphate-buffered saline to a ﬁnal concentration of
2.5 · 107 cells ⁄mL. Quantiﬁcation of CMV DNA copy num-
bers was performed by amplifying nucleotides 106047–
106119 of the UL73 gene using real-time TaqMan PCR
(ABI Prism 7000; Applied Biosystems, Foster City, CA, USA)
with forward primer 5¢-CCTGGTGGACTATGCTTAATG,
reverse primer 5¢-GGAAGCAGCAATGTCGTAGTACAAT
and TaqMan MGB probe 5¢-FAM-ATTCTCATGGGAGCT-
TTT. Each reaction mixture contained 300 nM CMV primers,
200 nM probe and TaqMan PCR Universal Master Mix
containing AmpliTaq Gold DNA polymerase, dNTPs with
deoxyuridine triphosphate, AmpErase uracil-N-glycosylase
and optimised buffers (Applied Biosystems). TaqMan
Exogenous Internal Positive Control Reagent (Applied
Biosystems) was added to distinguish negative reactions
from PCR inhibition. PCR conditions comprised 50C for
2 min and 95C for 10 min, followed by 40 cycles of 95C for
15 s and 60C for 1 min. To establish a standard curve, a
plasmid containing the target sequence of the CMV UL73
gene was constructed using pGEM-T Easy (Promega,
Madison, WI, USA). Puriﬁed plasmid DNA was quantiﬁed
using a spectrophotometer, and the number of plasmid
copies was calculated. Quantiﬁcation of CMV DNA in the
test samples was achieved by comparison with serial ten-
fold dilutions of the previously quantiﬁed plasmid stan-
dards. The plasmid standards and test samples were
assayed in duplicate, with the ﬁnal data presented as copy
numbers of DNA ⁄lL of buffy coat (copies ⁄ lL).
Measurement of CMV-speciﬁc IgG
CMV IgG titres in plasma were measured using an AxSYM
CMV IgG kit (Abbott Laboratories, Chicago, IL, USA),
based on microparticle enzyme immunoassay technology.
Anti-CMV IgG levels were expressed as numbers of
antibody units ⁄mL. These units were derived from the
standard calibration prepared from human samples by
Abbott Laboratories. Samples with zero to highest
concentrations are deﬁned as 0–250 absorbance units
(AU) ⁄mL. Values of >250 AU ⁄mL were obtained after serial
dilution.
Evidence of host response
Measurement of tumour necrosis factor (TNF)-a and interferon
(IFN)-c. Blood samples were anticoagulated with EDTA.
Plasma was separated from blood cells by low-speed centri-
fugation for 10 min. All samples were stored at )70C. Plasma
TNF-a and IFN-c levels were measured using commercially
available quantitative sandwich immunoassay kits (R&D
Systems, Minneapolis, MN, USA).
CMV-associated clinical ﬁndings. Patients were questioned
concerning symptoms such as anorexia, diarrhoea, pyrexia,
malaise and respiratory symptoms, and laboratory data,
including abnormal liver function tests, thrombocytopenia,
monocytosis and abnormal chest radiograph ﬁndings, were
recorded. For the present study, it was assumed that the
higher the number of potentially CMV-associated clinical
ﬁndings, the higher the possibility of reactivated CMV
infection. Thus, each of the possible ﬁndings listed above
was assessed at each visit, with a score of one being given to
each. The maximum score was nine. The score was averaged
for all 15 participants at each visit, and the averages for all
seven visits were compared.
Statistics
All results are presented as means ± standard error. Changes
over time (months) in the outcome measures were analysed by
repeated-measures analysis of variance (ANOVA), followed
by Newman–Keals post-test using PRISM v.3.0 statistical
software (GraphPad, San Diego, CA, USA), with p <0.05 being
regarded as statistically signiﬁcant.
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RESULTS
Patient characteristics
Of the 15 participants (11 men; mean
age 54.5 ± 9.04 years, range 38–71 years), 11 had
head and neck cancers, two had lung cancer, one
had lymphoma and one had rectal cancer. The
chemotherapy regimen received by each patient
was standard treatment for each speciﬁc cancer,
with the exception of patient 7, who received
geﬁtinib (Table 1). All participants received
3.3 mg of dexamethasone intravenously once
before each course of chemotherapy. One partic-
ipant (patient 12) received intermittent high-dose
corticosteroids during the study period for under-
lying rheumatoid arthritis.
Dynamics of CMV DNA in leukocytes during
chemotherapy
Ten of the 15 participants had no detectable viral
DNA in their baseline leukocyte samples before
starting chemotherapy. The viral load increased in
14 of 15 patients after chemotherapy commenced,
reaching a peak after the third course (Fig. 1) in ten
participants. The highest CMV viral loads were
>100 000 copies ⁄mL in two patients. As the viral
load increased, the patients experienced more
symptoms and showed more abnormal laboratory
tests. Patient 3 experienced anorexia, malaise and
diarrhoea, and had an abnormal liver function
test. Patient 5 experienced anorexia, pyrexia, dysp-
noea and malaise. The leukocyte viral loads subse-
quently decreased gradually without any antiviral
therapy, indicating that CMV reactivation in these
patients was self-limiting. As indicated in Table 1,
the highest CMV DNA loads were found in
patients who died (median 26 790 copies ⁄mL;
range 1130–275 060), while lower CMV loadswere
associated with patients who survived (median
1540 copies ⁄mL; range 0–19 440).
Host response
CMV-speciﬁc IgG. All participants were seroposi-
tive for CMV-speciﬁc IgG before chemotherapy
(Fig. 2). The titres rose in 11 of the subjects after
chemotherapy was commenced. In most patients,
the peak anti-CMV IgG titre was detected after
the appearance of peak viral loads. These
increased titres, especially those peaking after
peak viral loads, indicated an active host im-
mune response to CMV replication.
Table 1. Demographical data, diag-
nosis and treatment of 15 patients
with newly diagnosed cancer Patient
Age
(years) Gender Disease
Chemotherapy
regimen Outcome
Maximum recorded
cytomegalovirus
load (copies ⁄mL)
1 52 M Lung cancer Cisplatin, 5-FU Death 275 060 (3)a
2 49 M Oral cancer Cisplatin, 5-FU Death 215 190 (3)
3 54 M NPC Cisplatin, 5-FU Death 34 140 (3)
4 70 M NPC 5-FU, leucovorin Survival 19 440 (3)
5 52 M NPC Cisplatin, 5-FU Death 19 440 (3)
6 71 F Rectal cancer 5-FU, leucovorin Survival 6 320 (2)
7 58 M NPC Cisplatin, 5-FU Survival 2 800 (3)
8 48 F Lymphoma Epirubicin, vincristine Death 2 510 (3)
9 65 F NPC Cisplatin, 5-FU Survival 2 510 (4)
10 49 M HPC Cisplatin, 5-FU Survival 1 540 (2)
11 53 M Lung cancer Cisplatin, etoposide Death 1 130 (3)
12 38 M Oral cancer Geﬁtinib Survival 280 (4)
13 50 M Tongue cancer Cisplatin, 5-FU Survival 270 (3)
14 61 M NPC Cisplatin, 5-FU Survival 200 (4)
15 47 F NPC Cisplatin, 5-FU Survival 0
NPC, nasopharyngeal cancer; HPC, hypopharyngeal cancer; 5-FU, ﬂuorouracil.
aNumber in parentheses indicates the chemotherapy course with the maximal viral load.
Fig. 1. Mean cytomegalovirus (CMV) counts in leukocytes
as determined by real-time quantitative PCR at baseline
and after each course of chemotherapy. Ten of 15 partic-
ipants had undetectable virus at baseline before starting
chemotherapy. The peak recorded viral load was found
after the third course of chemotherapy, with ten patients
reaching a maximum viral load after the third to fourth
course of chemotherapy. *p <0.05, course 3 compared to
courses 0, 1, 2, 4, 5 and 6.
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TNF-a and IFN-c. TNF-a and IFN-c levels decrea-
sed from baseline after initiation of chemother-
apy, but then rose above baseline to maximum
levels after the fourth course of chemotherapy
(Figs 3 and 4). TNF-a levels peaked simulta-
neously with the peak viral load in three patients,
and after the peak viral load in ten patients. Peak
IFN-c levels occurred at the same time as the peak
viral load in one patient, but after the peak viral
load in seven patients. The timing of the rise in
the cytokine levels in relation to the rise in virus
titres suggests that TNF-a and IFN-c levels
increased in plasma in response to CMV replica-
tion. This is consistent with a normal host
immune response to a replicating virus.
Clinical ﬁndings. Scores for symptoms and abnor-
mal laboratory data that may have been associ-
ated with CMV reactivation peaked after the
second course of chemotherapy before the peak
viral load. All CMV-associated symptoms resol-
ved, except in one participant who had persistent
fever and respiratory symptoms after the sixth
course of chemotherapy (Fig. 5). The appearance
of symptoms and abnormal test results thus
paralleled the increasing viral load, but then
resolved as antibody titres and serum cytokines
increased (Table 2).
DISCUSSION
This pilot study demonstrated that all except one
of the CMV-seropositive patients experienced
CMV reactivation during the course of chemo-
therapy. Similar observations have been reported
in adults with haematological malignancies,
among whom CMV pneumonia is an important
cause of mortality [9,10]. The incidence of CMV
pneumonia in such patients (<3%) is thought to
be far less than in patients receiving solid-organ
Fig. 2. Mean cytomegalovirus (CMV)-speciﬁc IgG in base-
line blood samples and after each course of chemotherapy.
The recorded anti-CMV IgG titre of nine patients peaked
after the recorded viral load peak.
Fig. 3. Mean tumour necrosis factor (TNF)-a plasma levels
at baseline and after each course of chemotherapy. The
level peaked in three patients at the same time as the
recorded peak viral load, and in ten patients after the
recorded viral load peak.
Fig. 4. Mean interferon (IFN)-c plasma levels at baseline
and after each course of chemotherapy. Seven (46.7%)
participants had the highest levels of IFN-c after the
recorded viral load peak.
Fig. 5. Mean combined score for cytomegalovirus-associ-
ated symptoms and laboratory ﬁndings at baseline and
after each course of chemotherapy. The peak score
preceded the recorded peak number of viral particles.
*p <0.05, course 2 compared to courses 0, 1, 4, 5 and 6.
p <0.05, course 3 compared to courses 0, 1, 4, 5 and 6.
224 Clinical Microbiology and Infection, Volume 14 Number 3, March 2008
 2007 The Authors
Journal Compilation  2007 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14, 221–227
transplantation (>15%). There are also a number
of reports concerning CMV reactivation in
patients receiving chemotherapy; however, these
are mostly related to stem-cell transplantation [2],
solid-organ transplantation [7] or speciﬁc immuno-
suppressants [11].
Increasing use of cytoreductive therapy that
signiﬁcantly suppresses cellular immunity is
believed to be one of the key factors that expose
patients to a greater risk of severe CMV disease.
However, none of the participants in the present
study received major immunosuppressive agents,
e.g., purine analogues, cyclophosphamide or
large doses of systemic steroids. It is believed
that the present ﬁndings are most consistent with
a scenario in which the patients’ latent CMV was
reactivated when chemotherapy was commenced,
as clearly demonstrated by the increasing viral
load. At the same time that the viral load was
increasing, the patients began experiencing non-
speciﬁc symptoms and laboratory abnormalities
were found.
It has been shown previously that the existence
of high CMV DNA levels in the blood is a major
risk-factor for developing CMV disease. The viral
loads in two of the patients in the present study
rose to >100 000 copies ⁄mL. This represents a
critical threshold at which even relatively small
increases in viral load correspond to rapid
increases in the probability of disease, which is a
phenomenon termed the ‘threshold concept of
CMV disease’ [11]. As the viral load peaked, the
patients experienced more symptoms, but with-
out obvious CMV disease. It is possible that the
immunity against viral disease was not fully
suppressed by the non-cytoreductive chemother-
apy. In these patients, these non-speciﬁc symp-
toms and laboratory abnormalities cannot, in
themselves, be proven to be CMV-induced. How-
ever, an increase in anti-CMV IgG antibody titres
and cytokines followed the increased viral load.
As these peaked, the symptoms largely resolved
(except in one patient) and they did not reappear
during the rest of the course of chemotherapy.
The highest symptom scores, although relatively
low with a mean score of 2 ⁄ 9, were found to
precede the highest viral load. This implies that
the patients’ immunity was responding actively
to the replicating virus, and the symptoms began
to subside while the continuing elevated viral
load was halted by multiple defence systems.
Clearly, it is not possible to reach speciﬁc conclu-
sions concerning the value of the symptom scores
on the basis of this small study, but these data
provide a basis for further studies.
Most patients had measurable baseline plasma
levels of TNF-a and IFN-c; these became virtually
undetectable after the ﬁrst or second course of
chemotherapy, but then rose and peaked with, or
just after, the peak in CMV viral load. As with the
symptoms and laboratory abnormalities, this time
course suggests that the cytokines were expressed
in response to CMV replication, as might be
expected as part of the normal host immune
response against a replicating virus [12–14].
However, these ﬁndings are inconsistent with
the theory that inﬂammatory cytokines, such as
TNF-a, are major factors leading to the reactiva-
tion of latent CMV [15,16]. In addition, an
increased risk of CMV reactivation is often seen
in transplantation patients with elevated levels of
TNF-a [17]. TNF-a has been implicated in medi-
ating acute graft vs. host disease, which remains a
major cause of death in patients receiving alloge-
neic blood stem-cell transplantation.
Treatment with the human chimeric monoclo-
nal antibody inﬂiximab blocks the function of
TNF-a and has been used to treat steroid-refrac-
tory acute graft vs. host disease [18]. However,
inﬂiximab does not appear to decrease the inci-
dence of CMV-related infection in patients with
graft vs. host disease. Indeed, reports are accu-
mulating of patients treated with anti-TNF-a
antibody who have developed severe CMV
Table 2. Summary of evidence for cytomegalovirus (CMV) reactivation in 15 patients at baseline and at monthly intervals
after each course of chemotherapy (mean values are shown)
Baseline 1 2 3 4 5 6 p value
CMV viral load (copies ⁄mL) 273.2 ± 186.0 335.2 ± 242.0 1816 ± 1234 43 681 ± 25 203 1799 ± 1001 644.2 ± 245.0 449.0 ± 401.0 0.013
CMV-speciﬁc IgG (AU ⁄mL) 223.8 ± 42.6 240.8 ± 49.1 233.3 ± 55.3 316.7 ± 49.6 572.8 ± 158.0 449.8 ± 130.7 258.4 ± 17.3 0.011
TNF-a (pg ⁄mL) 1.366 ± 0.394 0.292 ± 0.270 0.334 ± 0.223 1.858 ± 0.454 2.000 ± 0.530 1.689 ± 0.428 1.228 ± 0.568 0.023
IFN-c (pg ⁄mL) 0.053 ± 0.053 0 0.513 ± 0.443 0.150 ± 0.150 3.779 ± 2.546 0 0.968 ± 0.968 0.109
Symptom score 0.067 ± 0.067 0.400 ± 0.235 1.933 ± 0.452 1.267 ± 0.331 0.467 ± 0.133 0.400 ± 0.214 0.133 ± 0.133 <0.001
AU, absorbance units; TNF, tumour necrosis factor; IFN, interferon.
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disease [19–21], such that caution has been
expressed concerning this treatment [22]. It was
thought originally that measurement of plasma
TNF-a might predict CMV reactivation during
conventional chemotherapy, whereas the results
in the present series suggest that increases in
TNF-a levels in this setting mainly reﬂect the host
immune response to a replicating virus rather
than virus reactivation. Similarly, the rise in
CMV-speciﬁc IgG, with peak levels occurring
mostly after viral loads peaked, may not limit
viral replication, but can be interpreted as indi-
cating an active host immune reaction to CMV
replication.
The present study was not designed to explore
the question of treatment for patients receiving
conventional chemotherapy who have clinically
apparent reactivation of CMV. Reactivation of
CMV and Epstein–Barr virus is considered to be
rare in patients with solid tumours who are
receiving conventional chemotherapy, and pro-
phylactic therapy is therefore not recommended
[23]. Certainly, treatment should be given to
patients with established infection, particularly
when it is severe. However, none of the patients in
the present study had documented CMV disease
according to current deﬁnitions, although evi-
dence has been presented that they may have been
mildly symptomatic because of viral reactivation.
Treatment would not normally be indicated for
such mild and apparently self-limited disease.
The main limitations of the present study were
the small number of patients and the limited
categories of malignancies. However, four con-
clusions can be reached from the ﬁndings. First, it
appears that CMV reactivation during conven-
tional chemotherapy may occur in a high propor-
tion of patients. Second, this reactivation is not
necessarily asymptomatic, but is probably self-
limiting in many patients. Third, given the course
of events, humoral immunity, as assessed by
CMV-speciﬁc IgG, seems to respond actively to
CMV reactivation. Finally, CMV reactivation is
apparently not preceded by an increase in plasma
TNF-a and IFN-c levels, suggesting that these
cytokines are expressed as part of the host
response to viral replication rather than being a
cause of it. Investigations of larger groups of
patients with a variety of cancers and different
types of chemotherapy are needed to conﬁrm the
scope and impact of CMV reactivation during
conventional chemotherapy.
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